Among 201 patients with invasive breast cancer, the molecular subtype was luminal A in 58 (28.9%), luminal B in 99 (49.3%), HER2-positive in 18 (9.0%), and triple-negative in 26 (12.9%). This evidence concerns the gene ERBB2 and invasive breast carcinoma.